REG - Beximco Pharma. - AGM Notification

Beximco PharmaceuticalsAnnouncement

19/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241119:nRSS6600Ma&default-theme=true

RNS Number : 6600M  Beximco Pharmaceuticals Ltd  19 November 2024

19 November 2024

 

BEXIMCO PHARMACEUTICALS LIMITED

 

AGM Notification

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, today
announces that the forty-eighth Annual General Meeting of Shareholders (AGM)
of Beximco Pharma will be held on Sunday, the 29th December, 2024 at 10.30 am
Bangladesh time under the Virtual Platform through
https://bxpharma.bdvirtualagm.com (https://bxpharma.bdvirtualagm.com) to
transact the following business:

 

AGENDA

 

ORDINARY BUSINESS:

 

1.   To receive, consider and adopt the Audited Financial Statements of the
Company for the year ended on 30th June, 2024 together with reports of the
Auditors and the Directors thereon.

2.   To declare 40% cash dividend as recommended by the Board of Directors.

3.   To elect Directors.

4.   To approve the appointment of Managing Director.

5.   To approve the re-appointment of Independent Director.

6.   To appoint Statutory Auditors for the year 2024-25 and to fix their
remuneration.

7.   To appoint Corporate Governance Compliance Auditors for the year
2024-25 and to fix their remuneration.

 

SPECIAL BUSINESS:

 

To pass Special Resolutions to change the name of the Company from "Beximco
Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC" as per the provision
of the Companies Act, 1994 (as amended in 2020) and to effect the change of
the name in the relevant Clauses of the Memorandum and Articles of Association
of the Company.

 

The draft of the Special Resolutions proposed to be passed is given below:

 

"Resolved that the name of the Company be changed from Beximco Pharmaceuticals
Limited to Beximco Pharmaceuticals PLC and the new name of the Company be
incorporated in the Memorandum and Articles of Association of the Company and
an amended copy of the Memorandum and Articles of Association of the Company
be and is hereby adopted and the same be filed with the Registrar of Joint
Stock Companies, Dhaka, Bangladesh for record."

 

 Dated: November 18, 2024  By order of the Board,

                           Sd/-

                           (MOHAMMAD ASAD ULLAH, FCS)

                           EXECUTIVE DIRECTOR & COMPANY SECRETARY

 

 

NOTES:

(1)  The Shareholders whose names appear in the Share Register of the Company
or in the Depository Register on the record date i.e. 25 November, 2024 will
be entitled to receive the dividend and to attend the Annual General Meeting.

 

(2)  A Member entitled to attend and vote at the General Meeting may appoint
a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped,
must be deposited at the Share Department of the Company at BEL Tower,
Level-2, 19 Dhanmondi, Road No.1, Dhaka-1205, no later than 48 hours before
the time fixed for the meeting.

 

(3)  Annual Report for the year 2023-24 will be sent through e-mail address
of the valued Shareholders and will be available in the Website of the Company
at: www.beximcopharma.com (http://www.beximcopharma.com) .

 

(4)  The valued Shareholders will join the Virtual AGM through the Link
https://bxpharma.bdvirtualagm.com (https://bxpharma.bdvirtualagm.com) . The
Shareholders will be able to submit their questions/comments and vote
electronically 24 (Twenty-four) hours before commencement of the AGM and also
during the AGM. For logging into the system, the Shareholders need to put
their 16-digit Beneficial Owner (BO) ID/Folio Number and other credential as
proof by visiting the said Link.

 

(5)  We encourage the Shareholders to login into the system prior to the
meeting. Please allow ample time to login and establish your connectivity. For
any IT related guidance, Shareholders may contact vide email :
monir@beximco.net (mailto:monir@beximco.net) or mazibur@beximco.net
(mailto:mazibur@beximco.net) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUWVORSKUAAAA